JP2019529433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529433A5 JP2019529433A5 JP2019515291A JP2019515291A JP2019529433A5 JP 2019529433 A5 JP2019529433 A5 JP 2019529433A5 JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019529433 A5 JP2019529433 A5 JP 2019529433A5
- Authority
- JP
- Japan
- Prior art keywords
- rirotomabu
- satetorakisetan
- administration
- lymphoma
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 16
- 229960004641 rituximab Drugs 0.000 claims 6
- 230000000527 lymphocytic effect Effects 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 231100000226 haematotoxicity Toxicity 0.000 claims 1
- 229950001237 lilotomab Drugs 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189191 | 2016-09-16 | ||
| EP16189191.6 | 2016-09-16 | ||
| EP17164164 | 2017-03-31 | ||
| EP17164164.0 | 2017-03-31 | ||
| EP17170641.9 | 2017-05-11 | ||
| EP17170641 | 2017-05-11 | ||
| EP17175768.5 | 2017-06-13 | ||
| EP17175768 | 2017-06-13 | ||
| PCT/EP2017/073336 WO2018050851A1 (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529433A JP2019529433A (ja) | 2019-10-17 |
| JP2019529433A5 true JP2019529433A5 (OSRAM) | 2020-10-22 |
Family
ID=59895313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515291A Pending JP2019529433A (ja) | 2016-09-16 | 2017-09-15 | リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190192703A1 (OSRAM) |
| EP (1) | EP3512881A1 (OSRAM) |
| JP (1) | JP2019529433A (OSRAM) |
| KR (1) | KR20190054113A (OSRAM) |
| CN (1) | CN109790219A (OSRAM) |
| AU (1) | AU2017327772A1 (OSRAM) |
| BR (1) | BR112019004838A2 (OSRAM) |
| CA (1) | CA3035268A1 (OSRAM) |
| IL (1) | IL265387A (OSRAM) |
| MX (1) | MX2019003029A (OSRAM) |
| PH (1) | PH12019550033A1 (OSRAM) |
| RU (1) | RU2019110955A (OSRAM) |
| SG (2) | SG11201901672RA (OSRAM) |
| WO (1) | WO2018050851A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7266576B2 (ja) * | 2017-08-04 | 2023-04-28 | ブリストル－マイヤーズ スクイブ カンパニー | ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物 |
| WO2019101789A1 (en) * | 2017-11-22 | 2019-05-31 | Nordic Nanovector Asa | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
| KR20240083769A (ko) | 2022-12-05 | 2024-06-12 | 김원석 | 휴대할 수 있는 해수 정화 유닛용 물통 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100389825C (zh) * | 1999-08-11 | 2008-05-28 | 拜奥根Idec公司 | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| RU2658438C2 (ru) * | 2011-12-13 | 2018-06-21 | Нордик Нановектор Аса | Химерное терапевтическое антитело нн1 против cd-37 |
| WO2016138034A1 (en) * | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
-
2017
- 2017-09-15 US US16/329,661 patent/US20190192703A1/en not_active Abandoned
- 2017-09-15 AU AU2017327772A patent/AU2017327772A1/en not_active Abandoned
- 2017-09-15 MX MX2019003029A patent/MX2019003029A/es unknown
- 2017-09-15 JP JP2019515291A patent/JP2019529433A/ja active Pending
- 2017-09-15 CN CN201780055437.7A patent/CN109790219A/zh active Pending
- 2017-09-15 SG SG11201901672RA patent/SG11201901672RA/en unknown
- 2017-09-15 CA CA3035268A patent/CA3035268A1/en active Pending
- 2017-09-15 BR BR112019004838A patent/BR112019004838A2/pt not_active IP Right Cessation
- 2017-09-15 KR KR1020197010585A patent/KR20190054113A/ko not_active Ceased
- 2017-09-15 WO PCT/EP2017/073336 patent/WO2018050851A1/en not_active Ceased
- 2017-09-15 EP EP17768448.7A patent/EP3512881A1/en not_active Withdrawn
- 2017-09-15 RU RU2019110955A patent/RU2019110955A/ru unknown
- 2017-09-15 SG SG10202102588QA patent/SG10202102588QA/en unknown
-
2019
- 2019-03-07 PH PH12019550033A patent/PH12019550033A1/en unknown
- 2019-03-14 IL IL265387A patent/IL265387A/en unknown
-
2021
- 2021-06-22 US US17/304,541 patent/US20220160907A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2017008088A5 (OSRAM) | ||
| JP2016539156A5 (OSRAM) | ||
| PH12015502317A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
| NZ609201A (en) | Means and methods for treating dlbcl | |
| MX2010010026A (es) | Agente para tratar enfermedad. | |
| JP2008519047A5 (OSRAM) | ||
| MY164352A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| NO20062398L (no) | Daglig, oral, kontrollert frigivnings oksycodon-doserings form | |
| MY173881A (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
| UY31305A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| McCarthy et al. | In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
| JP2019529433A5 (OSRAM) | ||
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| JP2016515619A5 (OSRAM) | ||
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| MX2010005198A (es) | Composiciones liquidas que comprenden valsartan. | |
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| RU2019110955A (ru) | ЛЕЧЕНИЕ НЕХОДЖКИНСКОЙ ЛИМФОМЫ ЛИЛОТОМАБОМ И 177Lu-ЛИЛОТОМАБ САТЕТРАКСЕТАНОМ |